Technology

Non small cell lung cancer, Head and neck squamous cell carcinoma, Esophageal squamous-cell carcinomas

AP203 employs a dual-targeting mechanism that combines PD-L1 blocking with T-cube-enabled CD137 activation to enhance T cell activity while avoiding the risk of a cytokine storm. By blocking the interaction between tumor PD-L1 and T cell PD-1, AP203 prevents T cell suppression, allowing the immune system to better detect and attack cancer cells. At the same time, activating the CD137 signaling pathway promotes T cell proliferation and survival, leading to a more robust and sustained anti-tumor response. This mechanism re-directs activated T cells into the tumor microenvironment, enhancing the effectiveness of existing immunotherapies and offering a safer, comprehensive approach to cancer treatment.

1. Approval for Phase I clinical trials granted by the U.S. FDA in September 2022.
2. Approval for Phase I clinical trials granted by the Taiwan TFDA in November 2022.
3. In the process of international patent examination, U.S. patents have already been granted.
4. Part of preclinical study was presented as posters at the Immuno-Oncology Summit Europe 2022 conference in July 2022.
5. Part of preclinical studies were published in 2023 in the journal 'Journal of Translational Medicine,' titled 'A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity' [PubMed].

1. A true target-dependent T cell activation of the bispecific antibody, it activates cytotoxic T cells expressing CD137 only upon binding with both CD137 and PD-L1 on cancer cells. This design minimizes the risk of cytokine release syndrome typically associated with CD3-based bispecific antibodies, ensuring higher safety levels.
2. The bivalent binding activity of AP203 to both PD-L1 and CD137 is superior to monovalent binding of other bispecific antibodies. AP203 can efficiently trigger CD137 activation in T cells through PD-L1 clustering.
3. The oppositely binding regions of PD-L1 and CD137 facilitate the bridging between PD-L1-expressing cancer cells and CD137-expressing T cells without spatial hindrance. 
4. The symmetrical structure expressing only heavy and light chains is advantageous for antibody expression and formation. It can be adapted the downstream purification processes established for monoclonal antibodies, eliminating the need to develop new processes for asymmetric bispecific antibodies.

According to the latest global market analyses, the oncology therapeutics sector continues to expand at a rapid pace, significantly outpacing earlier projections. IQVIA’s 2024 report indicates that global cancer drug spending reached approximately US$223 billion in 2023, and is expected to surpass US$400 billion by 2028, reflecting the accelerating demand for innovative cancer therapies. Similarly, Precedence Research projects that the global oncology market will grow from US$250.88 billion in 2025 to US$668.26 billion by 2034, representing a robust 11.5% CAGR over the forecast period. Technavio also forecasts an additional US$215.9 billion of market expansion between 2024 and 2029, with a five-year CAGR of 13.4%.

Key drivers of this growth include the rising global cancer incidence, improved access to healthcare, and rapid advancements in precision medicine and immuno-oncology. Novel modalities—such as immune checkpoint inhibitors, T-cell engagers, bispecific antibodies, and cell therapies—are reshaping treatment paradigms and contributing to sustained long-term market expansion.

Overall, the global oncology market is entering a decade of accelerated growth, solidifying its position as one of the most dynamic and strategically important sectors in the biopharmaceutical industry.